Caribou Biosciences

Caribou Biosciences

  • Founded: 2012
  • Location: Berkeley, CA
  • Employee range: 50 - 200
  • Clinical stage: Clin1
  • Therapy area: B-cell NHL
  • Drug types: ONC
  • Lead product: CB-010
  • Product link:
  • Funding: $25M stock Jul 2023; $304M IPO Jul 2021; $115M C Mar 2021; $30M B May 2016; $11M A Apr 2015

job board

Short description:

Cellular Engineering Tools (CRISPR)

Drug notes:

CB-011 Clin1 multiple myeloma; CB-012 Clin0 AML; CB-020 RD solid tumors; 2 undisclosed programs RD undisclosed

Long description:

Caribou Biosciences is developing CRISPR technologies to create allogeneic cell therapies for oncology. Caribou has built CRISPR hybrid RNA-DNA (chRDNA), their proprietary technology that enables highly efficient, highly specific genome editing. chRDNA is then used to develop sophisticated genome-edited cell therapies. For example, Caribou is using chRDNA to create next-generation allogeneic CAR-T and CAR-NK cell therapies to enhance the longevity and persistence of the cells. Scientific advances have been published in high-impact journals. Caribou has one ongoing Phase I clinical trial to evaluate CB-010 in adults with relapsed B cell non-Hodgkin lymphoma.


Caribou Biosciences
Portfolio Vendor Leader
Berkeley, CA|36 days ago

© 2023 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy